

PROJECT PRESENTATION

1.	Program Title	HORIZON 2020 Systems approaches for the discovery of combinatorial therapies for complex disorders
2.	Call Title	H2020-SC1-BHC-2018-2020/H2020-SC1-2019-Two-Stage-RTD
3.	Project Title	Targeted Therapy for Advanced colorectal cancer patients – REVERT
4.	Project ID	848098
5.	Project coordinator/ manager	S.L. Herghelegiu Paul – Partener (LTP – cluster IMAGO-MOL) - AC
6.	Consortium (if any)	<p>1. ‘the coordinator’: SAN RAFFAELE ROMA SRL (San Raffaele), established in VIA DELLA PISANA 235, ROMA RM 00163, Italy, VAT number: IT10636891003, represented for the purposes of signing the Agreement by Legal representative, Carlo TRIVELLI and the following other beneficiaries, if they sign their ‘Accession Form’ (see Annex 3 and Article 56):</p> <p>2. AZIENDA ULSS 4 VENETO ORIENTALE (ULSS 4 - ProMIS), established in PIAZZA DE GASPERI 5, SAN DONA DI PIAVE 30027, Italy, VAT number: IT02799490277,</p> <p>3. MALMO UNIVERSITET (MALMO UNIV.), established in NORDENSKIOLDSGATAN 1, MALMOE 205 06, Sweden, VAT number: SE202100492001,</p> <p>4. GENXPRO GMBH (GXP), established in ALTENHOFTER ALLEE 3, FRANKFURT 60438, Germany, VAT number: DE247777479,</p> <p>5. BUNDESANSTALT FUER MATERIALFORSCHUNG UND - PRUEFUNG (BAM), established in Unter den Eichen 87, BERLIN 12205, Germany, VAT number: DE136630222,</p>

		<p>6. UMEA UNIVERSITET (UMEA UNIV.), established in UNIVERSITETOMRADET, UMEA 901 87, Sweden, VAT number: SE202100287401,</p> <p>7. BIOVARIANCE GMBH (BioV), established in KONNERSREUTHER STR. 6G, WALDSASSEN 95652, Germany, VAT number: DE291742512,</p> <p>8. FUNDACION UNIVERSITARIA SAN ANTONIO (UCAM), established in AVDA JERONIMOS CAMPUS UNIVERSI S/N UNIVERSIDAD CATOLICA SAN ANTONIO, MURCIA 30107, Spain, VAT number: ESG30626303,</p> <p>9. INSTITUTUL REGIONAL DE ONCOLOGIE IASI (IRO IASSY), established in G-RAL HENRI MATHIAS BERTHELOT NR 2-4, IASI 700483, Romania, VAT number: RO29067408,</p> <p>10. SERVICIO MURCIANO DE SALUD (SMS), established in C CENTRAL 7, MURCIA 30100, Spain, VAT number: ESQ8050008E,</p> <p>11. LUXEMBOURG INSTITUTE OF HEALTH (LIH), established in VAL FLEURI 84, LUXEMBOURG 1526, Luxembourg, VAT number: LU14472612,</p> <p>12. CLUSTERUL REGIONAL INOVATIV DE IMAGISTICA MOLECULARA SI STRUCTURALA NORD-EST (IMAGO-MOL) (IMAGO-MOL), established in 16 UNIVERSITATII ST BUILDING A1 GROUND FLOOR, IASI 700115, Romania,</p> <p>13. OLOMEDIA SRL (Olomedia), established in VIA SIMONE CUCCIA 46, PALERMO 90144, Italy, VAT number: IT05715380829,</p> <p>14. UNIVERSITA DEGLI STUDI DI ROMA TOR VERGATA (UNITOV), established in VIA CRACOVIA 50, ROMA 00133, Italy, VAT number: IT02133971008</p>
7.	Project budget – Total value (Lei/Euro)	5887273.75 Euro
8.	Project budget – TUIASI value (Lei/Euro)	48.125,00 Euro
9.	Implementation period	01.01.2020-31.12.2023

10.	Main objective/s	The main objective of REVERT is to develop an improved and innovative model of combinatorial therapy – based on personalised medicine – that identifies the most efficient and cost-effective therapeutic intervention for patients with unresectable metastatic colorectal cancer (mCRC).
11.	Project activity/es	<ul style="list-style-type: none"> ▪ To build the REVERT-DataBase (RDB) to re-analyse and characterise the pathophysiology of mCRC and to investigate the causes of positive or negative responses to treatments based on established therapeutic interventions in patients with unresectable mCRC. RDB is built upon a large number of standardized biobank samples with related structured data, and clinical databases from several major European clinical centres; ▪ To assess the significance of biomarkers and molecular predictors of therapeutic response or disease outcome in subjects with mCRC using an innovative AI-model implemented with data from large European clinical databases and biobanks; ▪ To screen and characterize molecular mechanisms of already approved drugs as potential novel candidates for combination therapy to effectively target metastatic cancer by using patient tumour-derived organoids models; ▪ To validate the health, economic and social impact of the model in preclinical/ clinical studies across Europe; ▪ To build an EU- network among SMEs, research institutions, clinical centres and biobanks focused on R&D in the field of AI-Health for the development of personalised medicine.
12.	Project result/s	<ul style="list-style-type: none"> ▪ To build a sophisticated computational framework based on AI to predict patient responses to combinatorial therapies for mCRC care, based on the analysis of new, potential prognostic biomarkers (e.g., gene mutations, epigenetic changes, gene expression profiling signatures) as molecular predictors of therapeutic response, treatment resistance or disease outcome, in comparison with established therapeutic interventions;

13.	Project website (if any)	https://www.revert-project.eu/
14.	Project photo/s (if any)	On the website